Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.
You may also be interested in...
FDA Seeks Pediatric Review Of Four Cancer Drugs With Hard-to-study Populations
ODAC's pediatric subcommittee will consider pediatric development plans and the formulation of written requests for Allos' Folotyn, Amgen's Prolia, Eisai's eribulin and Pfizer's crizotinib.
FDA Seeks Pediatric Review Of Four Cancer Drugs With Hard-to-study Populations
ODAC's pediatric subcommittee will consider pediatric development plans and the formulation of written requests for Allos' Folotyn, Amgen's Prolia, Eisai's eribulin and Pfizer's crizotinib.
FDA Cites Meta-Analysis To Validate Surrogate Endpoint for Pfizer's Revatio
Advisory committee will be asked to support the use of a hemodynamic endpoint in pediatric trials of Pfizer's Revatio (sildenafil).